JFL Life

Why is JFL Life Sciences Ltd falling/rising?

As of 28-Jun, JFL Life Sciences Ltd's stock price is at 9.05, unchanged from the previous day, and has significantly underperformed with a year-to-date drop of 27.60%. The stock is trading below all moving averages and has seen a 61.54% decline in investor participation, indicating a bearish trend.

As of 28-Jun, JFL Life Sciences Ltd's stock price is currently at 9.05, with no change from the previous day. The stock has shown a significant decline over various periods, with a year-to-date drop of 27.60% and a one-year decrease of 40.26%. In comparison, the benchmark Sensex has only fallen by 7.94% over the same year-to-date period, indicating that JFL Life is underperforming relative to the market.<BR><BR>In today's trading, the stock has outperformed its sector by 0.28%, but it is trading below all its moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages. This suggests a bearish trend in the stock's performance. Additionally, there has been a notable decline in investor participation, with delivery volume dropping by 61.54% compared to the 5-day average, indicating reduced interest from investors.<BR><BR>Overall, the combination of poor historical performance, low investor participation, and trading below moving averages contributes to the perception that JFL Life Sciences Ltd is experiencing a downward trend in its stock price.

Which are the latest news on JFL Life?

What does JFL Life do?

JFL Life Sciences Ltd is a Micro Cap company that manufactures and markets pharmaceutical products. It was incorporated in 2010, became a public company in 2022, and reported net sales of 63 Cr and a net profit of 2 Cr for the quarter ending March 2026.

Overview: <BR>JFL Life Sciences Ltd manufactures and markets pharmaceutical products and operates within the Pharmaceuticals & Biotechnology industry, classified as a Micro Cap company.<BR><BR>History: <BR>JFL Life Sciences Ltd was incorporated as 'JFL Life Sciences Private Limited' on April 25, 2010. The company transitioned from a Private Limited to a Public Limited Company following a Special Resolution on February 10, 2022, and subsequently changed its name to 'JFL Life Sciences Limited' on March 3, 2022. The latest quarterly results reported are for March 2026.<BR><BR>Financial Snapshot: <BR>Net Sales: 63 Cr (Quarterly Results - Mar 2026) <BR>Net Profit: 2 Cr (Quarterly Results - Mar 2026) <BR>Market Cap: INR 65 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: 10.00 <BR>Industry P/E: 34 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 0.44 <BR>Return on Equity: 13.95% <BR>Price to Book: 1.42 <BR><BR>Contact Details: <BR>Details: No Company Details Available <BR>Registrar Address: Not available.

How big is JFL Life?

As of 10th June, JFL Life Sciences Ltd has a market capitalization of 65.00 Cr, with recent net sales of 131.39 Cr and a net profit of 6.40 Cr. The company reported shareholder's funds of 39.46 Cr and total assets of 71.91 Cr for the annual period ending March 2025.

As of 10th June, JFL Life Sciences Ltd has a market capitalization of 65.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, JFL Life reported Net Sales of 131.39 Cr and a Net Profit of 6.40 Cr.<BR><BR>For the latest annual period ending March 2025, the company had Shareholder's Funds of 39.46 Cr and Total Assets amounting to 71.91 Cr.

Who are in the management team of JFL Life?

The management team of JFL Life includes Smiral Ashwinkumar Patel (Managing Director), Manishkumar Jasvantlal Patel (Chairman), Tejal Smiral Patel (Whole-time Director), and independent directors Sonu Lalitkumar Jain and Bhavna Shah, along with Company Secretary Pratima Singh.

The management team of JFL Life includes the following individuals:<BR><BR>1. **Smiral Ashwinkumar Patel** - Managing Director<BR>2. **Manishkumar Jasvantlal Patel** - Chairman & Non-Executive Director<BR>3. **Tejal Smiral Patel** - Whole-time Director<BR>4. **Sonu Lalitkumar Jain** - Non-Executive & Independent Director<BR>5. **Bhavna Shah** - Non-Executive & Independent Director<BR>6. **Pratima Singh** - Company Secretary<BR><BR>If you have any more questions about JFL Life or its management, feel free to ask!

Who are the peers of the JFL Life?

JFL Life's peers include Zenith Drugs, Ajooni Biotech, and others, with varying management and growth risks. JFL Life shows average management risk and growth, with a 1-year return of -41.59%, significantly lower than its peers.

Peers: The peers of JFL Life are Zenith Drugs, Ajooni Biotech, Vineet Laborator, Biofil Chemicals, Sunil Healthcare, Samrat Pharma, Source Natural, Asston Pharmaceu, Phaarmasia, and Vivo Bio Tech.<BR><BR>Quality Snapshot: Excellent management risk is observed at Source Natural, while Average management risk is found at JFL Life and Samrat Pharma. Below Average management risk is noted for Zenith Drugs, Ajooni Biotech, Vineet Laborator, Biofil Chemicals, Sunil Healthcare, Phaarmasia, and Vivo Bio Tech, and the rest. JFL Life shows Excellent growth, while Average growth is seen at Ajooni Biotech and the rest. Below Average growth is reported for Zenith Drugs, Vineet Laborator, Biofil Chemicals, Samrat Pharma, and the rest. Good capital structure is noted at JFL Life, Ajooni Biotech, Biofil Chemicals, and Source Natural, while Below Average capital structure is found at Zenith Drugs, Vineet Laborator, Sunil Healthcare, Samrat Pharma, Phaarmasia, and Vivo Bio Tech, and the rest.<BR><BR>Return Snapshot: Vineet Laborator has the highest 1-year return at 58.84%, while JFL Life has the lowest at -41.59%. JFL Life's 1-year return is significantly lower than the highest peer return. Additionally, Zenith Drugs, Ajooni Biotech, JFL Life, and Phaarmasia all have negative six-month returns.

Should I buy, sell or hold JFL Life Sciences Ltd?

Are JFL Life Sciences Ltd latest results good or bad?

JFL Life Sciences Ltd's latest results show a significant quarter-over-quarter sales increase of 158.07%, but a 24.30% decline year-over-year, alongside reduced operating margins and ongoing profitability challenges, indicating a mixed and concerning financial outlook.

JFL Life Sciences Ltd's latest results present a mixed picture, reflecting significant volatility in its financial performance. On one hand, the company reported a remarkable 158.07% increase in net sales quarter-over-quarter, reaching ₹29.91 crores. However, this figure is still down 24.30% compared to the same quarter last year, indicating a challenging year-over-year performance.<BR><BR>The operating margin has contracted to 9.76%, down from 16.65% in the previous quarter, which raises concerns about the company's pricing power and cost management. While net profit saw a substantial increase of 162.67% QoQ to ₹1.97 crores, it remains 35.86% lower than the prior year, highlighting ongoing profitability challenges.<BR><BR>Additionally, the nine-month performance for FY26 shows a decline in sales by 24.76% and a 38.46% drop in profit after tax compared to the same period last year. This suggests that the recent quarterly uptick may not be sustainable and raises questions about the overall health of the business.<BR><BR>Furthermore, the absence of institutional investors and the company's reliance on sporadic bulk orders rather than steady revenue streams contribute to a perception of instability. Overall, while there are some positive indicators in the latest results, the underlying issues and volatility suggest that the company's performance is more concerning than reassuring at this time.

How has been the historical performance of JFL Life?

JFL Life has shown significant growth in net sales and profitability, with net sales increasing from 30.17 Cr in Mar'20 to 82.04 Cr in Mar'25, and profit after tax rising from 0.36 Cr to 4.16 Cr during the same period. However, cash flow from operations has been volatile, turning negative at -3.00 Cr in Mar'25.

Answer:<BR>The historical performance of JFL Life shows a significant growth trend in net sales and profitability over the past few years.<BR><BR>Breakdown:<BR>JFL Life's net sales have increased from 30.17 Cr in Mar'20 to 82.04 Cr in Mar'25, indicating a robust growth trajectory. Total operating income has followed a similar pattern, rising from 30.17 Cr to 82.04 Cr during the same period. The company's total expenditure, excluding depreciation, has also grown, reaching 73.85 Cr in Mar'25 from 28.31 Cr in Mar'20. Operating profit, which reflects the company's operational efficiency, has improved from 1.86 Cr in Mar'20 to 8.20 Cr in Mar'25, while profit before tax has increased from 0.50 Cr to 6.14 Cr in the same timeframe. Profit after tax has also seen a rise from 0.36 Cr in Mar'20 to 4.16 Cr in Mar'25. The company's earnings per share (EPS) have fluctuated, peaking at 10.8 in Mar'21 before settling at 1.26 in Mar'25. On the balance sheet, total assets have grown from 48.26 Cr in Mar'22 to 71.91 Cr in Mar'25, with total liabilities also increasing from 48.26 Cr to 71.91 Cr. The cash flow from operating activities has been negative in Mar'25 at -3.00 Cr, contrasting with a positive cash flow of 8.00 Cr in Mar'24. Overall, JFL Life has demonstrated significant growth in sales and profitability, although cash flow from operations has shown volatility.

How has been the historical performance of JFL Life?

JFL Life has shown significant growth in net sales and profitability, with net sales increasing from 30.17 Cr in Mar'20 to 82.04 Cr in Mar'25, and profit after tax rising from 0.36 Cr to 4.16 Cr during the same period, despite some cash flow challenges. Total assets and liabilities also grew, reflecting the company's expanding operations.

Answer:<BR>The historical performance of JFL Life shows a significant upward trend in net sales and profitability over the years.<BR><BR>Breakdown:<BR>JFL Life's net sales have increased from 30.17 Cr in Mar'20 to 82.04 Cr in Mar'25, reflecting a strong growth trajectory. Total operating income followed a similar pattern, rising from 30.17 Cr in Mar'20 to 82.04 Cr in Mar'25. The raw material costs also rose, from 26.72 Cr in Mar'20 to 66.77 Cr in Mar'25, indicating increased production expenses. Operating profit, excluding other income, improved from 1.86 Cr in Mar'20 to 8.19 Cr in Mar'25, while profit before tax increased from 0.50 Cr to 6.14 Cr in the same period. Profit after tax also saw a rise from 0.36 Cr in Mar'20 to 4.16 Cr in Mar'25. The company's total assets grew from 48.26 Cr in Mar'22 to 71.91 Cr in Mar'25, with total liabilities increasing from 48.26 Cr to 71.91 Cr. Cash flow from operating activities showed fluctuations, with a negative cash flow of -3.00 Cr in Mar'25, contrasting with a positive cash flow of 8.00 Cr in Mar'24. Overall, JFL Life has demonstrated robust growth in sales and profitability, despite some challenges in cash flow management.

Who are the top shareholders of the JFL Life?

The top shareholder of JFL Life is Smiral Ashwinkumar Patel, holding 44.33% of the shares. The highest public shareholder is Pratik Rajendra Gandhi at 1.22%, while individual investors collectively own 28.99%.

The top shareholders of JFL Life primarily include the promoters, with Smiral Ashwinkumar Patel holding the largest share at 44.33%. There are no pledged promoter holdings, and the company does not have any mutual funds or foreign institutional investors (FIIs) holding shares. The highest public shareholder is Pratik Rajendra Gandhi, who owns 1.22%. Additionally, individual investors collectively hold 28.99% of the shares.

Is JFL Life overvalued or undervalued?

As of May 20, 2025, JFL Life is considered undervalued with a PE ratio of 15.59 and an EV to EBITDA of 8.61, showing significant improvement and potential for recovery despite a year-to-date decline of 39.02% compared to the Sensex's 6.24%.

As of 20 May 2025, JFL Life has moved from a grade of does not qualify to very attractive, indicating a significant improvement in its valuation outlook. The company is currently considered undervalued based on its financial metrics. Key ratios include a PE ratio of 15.59, an EV to EBITDA of 8.61, and a ROCE of 17.46%. <BR><BR>In comparison to its peers, JFL Life stands out with a much lower PE ratio than Sun Pharmaceutical Industries Ltd. at 35.25 and Divi's Laboratories Ltd. at 79.33, both of which are classified as expensive. The valuation metrics suggest that JFL Life is positioned favorably within the pharmaceuticals and biotechnology sector. Despite recent underperformance relative to the Sensex, with a year-to-date decline of 39.02% compared to the Sensex's 6.24%, the current valuation indicates a potential for recovery and growth.

What is the technical trend for JFL Life?

As of May 21, 2025, JFL Life's technical trend is mildly bearish, supported by negative signals from daily moving averages, Bollinger Bands, and KST, despite a mildly bullish weekly MACD.

As of 21 May 2025, the technical trend for JFL Life has changed from sideways to mildly bearish. The weekly MACD indicates a mildly bullish stance, but the monthly MACD is mildly bearish, suggesting mixed signals. The moving averages on the daily chart are also mildly bearish, reinforcing the negative outlook. Bollinger Bands and KST on the weekly are both bearish, while the Dow Theory shows a bearish trend on the weekly timeframe. The OBV is mildly bearish, indicating selling pressure. Overall, the current technical stance is mildly bearish, driven primarily by the daily moving averages and the bearish indicators from Bollinger Bands and KST.

When is the next results date for JFL Life?

No Upcoming Board Meetings

What is the bonus history of the JFL Life?

JFL Life recently announced a 2:1 bonus issue, where shareholders will receive two additional shares for every one share held as of the record date on September 24, 2024. The ex-date for this bonus is also September 24, 2024.

JFL Life has a recent bonus history where they announced a 2:1 bonus issue. The ex-date for this bonus is set for September 24, 2024. This means that shareholders will receive two additional shares for every one share they hold as of the record date, which is also September 24, 2024.

Has JFL Life declared dividend?

JFL Life Sciences Ltd has declared a 2% dividend, amounting to 0.20 per share, with an ex-date of September 13, 2024. Despite the dividend, the company has experienced significant declines in price returns over various periods, resulting in negative total returns.

JFL Life Sciences Ltd has declared a 2% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 2%<BR>- Amount per share: 0.20<BR>- Ex-date: 13 Sep 2024<BR><BR>Dividend Yield: 0.34%<BR><BR>Total Returns by Period:<BR>In the 6-month period, the price return was -40.45%, the dividend return was 0%, resulting in a total return of -40.45%.<BR><BR>For the 1-year period, the price return was -46.96%, the dividend return was 0.50%, leading to a total return of -46.46%.<BR><BR>Over the 2-year period, the price return was -51.78%, the dividend return was 0.52%, culminating in a total return of -51.26%.<BR><BR>In the 3-year period, the price return was 0%, the dividend return was 0%, resulting in a total return of 0.0%.<BR><BR>For the 4-year period, the price return was 0%, the dividend return was 0%, leading to a total return of 0.0%.<BR><BR>In the 5-year period, the price return was 0%, the dividend return was 0%, culminating in a total return of 0.0%.<BR><BR>Overall, while JFL Life has declared a dividend, the total returns over various periods indicate significant declines in price returns, with minimal contributions from dividends. This suggests a challenging performance environment for the company.